First-in-Human Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Rapidly Developed SARS-CoV-2 Therapeutic Antibody, AOD01, in Healthy Adults.

Venkateshan S PrativadibhayankaramLawrence Soon-U LeeDavid LyeXu XiaoyingRanjani NelloreVishal PendharkarHannes HentzeSiyu GuanBenjamin J AyersShirley G K SeahDe Hoe ChyeNajwa S N TalibNivashini KaliaperumalWei Yee OngZi Xin WongVeonice B AuAnshula AlokJohn E ConnollyJerome D Boyd-KirkupPiers J IngramBrendon J HansonKantharaj EthirajuluDamian O'ConnellConrad En Zuo Chan

Published in: Infectious diseases and therapy (2022)

AOD01 was safe and well tolerated, demonstrated dose-related PK, non-immunogenic status, and sustained ex vivo neutralization of SARS-CoV-2 after single intravenous dose ranging from 2 to 20 mg/kg and two doses of 20 mg/kg and show good potential for treatment of SARS-CoV-2 infection. (Health Sciences Authority identifier number CTA2000119).

Keyphrases

climate change
sars cov
respiratory syndrome coronavirus
endothelial cells
healthcare
public health
open label
high dose
coronavirus disease
randomized controlled trial
clinical trial
health information
combination therapy
risk assessment
study protocol